Takeda Pharmaceutical Company Limited

Jun Kunitomo

Takahiko Taniguchi

Masato Yoshikawa

Makoto Fushimi

Tomoaki Hasui

Shinkichi Suzuki

Hiroyuki Odaka

Hiromi Kobayashi

Hiroyuki Kimura

John Frederick Quinn

Keisuke Imamura

Tsuyoshi Maekawa

Takenori Hitaka

Haruhi Kamisaki

Eiji Honda

Eiji Kimura

Joseph Raker

Morihisa Saitoh

Fumio Itoh

Tomohiro Kawamoto

Hironori Kokubo

Kasei Miura

Katsuhito Murase

Shotaro Miura

Akira Kawada

Hiroki Iwashita

Mitsuyo Kondo

The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I): 

Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders

A compound having PDE inhibitory represented by formula (1), W-W(1), wherein (i) Wis and Wis (ii) Wis and Wis or (iii) Wis and Wis or a pharmaceutically acceptable salt thereof; and a method of treating or preventing schizophrenia.

Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors

The present invention provides a compound represented by the formula (1): wherein each symbol is as defined in the specification, or a salt thereof, a prodrug of the compound or a salt thereof, a medicament containing the compound or a salt thereof, the medicament which is a phosphodiesterase 10A inhibitor, and a medicament which is for preventing or treating schizophrenia.

Heterocyclic compound

The present invention provides a compound having a superior PDE10A inhibitory action and use thereof. The compound is a compound represented by the following formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

Condensed heterocyclic compound

The present invention provides a compound which has the effect of PDE 10A inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound represented by the formula (1'): wherein, Ring A&#x2032; represents an optionally substituted pyridine ring, an optionally substituted pyridazine ring, a pyrimidine ring, or 10 a pyrazine ring, R1&#x2032; represents (1) wherein, Rrepresents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B2 represents a bond, &#x2014;S&#x2014;, -0-, &#x2014;CO&#x2014;, an optionally substituted methylene group, or &#x2014;NR&#x2014; (Rrepresents a hydrogen atom, or an optionally substituted Calkyl group), and Ring Brepresents an optionally further substituted 6- to 10-membered aromatic hydrocarbon ring, or an optionally further substituted 5- to 10-membered aromatic heterocyclic ring, or alternatively, L&#x2032; and Rmay be taken together to form an optionally substituted bicyclic or tricyclic fused heterocyclic group, or (2), wherein, Rrepresents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring Brepresents an optionally substituted benzene ring, an optionally substituted pyridine ring, an optionally substituted pyrimidine ring, an optionally substituted pyrazine ring, or an optionally substituted pyridazine ring, Ring D&#x2032; represents an optionally further substituted 5- or 6-membered ring, Rrepresents a hydrogen atom, or a substituent, X&#x2032; represents &#x2550;N&#x2014; or &#x2550;CR&#x2014;(Rrepresents a hydrogen atom, or a substituent), - - - - - represents that Rand Rmay form, taken together with the carbon atom and the nitrogen atom to which they are each adjacent, an optionally substituted 5- to 7-membered ring when.X&#x2032; is &#x2550;CR, or a salt thereof.

Fused heterocyclic compounds

The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I), wherein R1 represents a substituent; R2 represents a hydrogen atom, or a substituent; R3 represents a hydrogen atom, or a substituent; Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof. 

Pyridazinone compounds

For the purpose of providing a GSK-3&#x3b2; inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3&#x3b2;-related pathology or disease, the present invention provides a GSK-3&#x3b2; inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

GSK-3&#x3b2; inhibitor

1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound

The present invention provides a retinoid-related receptor (except retinoic acid receptors) function regulating agent comprising a compound represented by the formula: wherein one of Rand Ris an optionally substituted monocyclic aromatic hydrocarbon group or an optionally substituted monocyclic aromatic heterocyclic group containing one heteroatom, and the other is a hydrogen atom and the like; B is a 5- or 6-membered heterocycle (except 1,3-azole); A is an optionally substituted aromatic hydrocarbon group or an optionally substituted aromatic heterocyclic group; and Ris a hydrogen atom and the like, or a salt thereof, which is useful as an agent for the prophylaxis or treatment of diabetes mellitus, hyperlipidemia, impaired glucose tolerance or the like.

Function regulator for retinoid relative receptor

Growing community of inventors

Kanagawa, Japan

Jun Kunitomo